Journal
ONCOGENE
Volume 33, Issue 26, Pages 3351-3360Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2013.275
Keywords
ATM; signalling; cancer
Funding
- ERC [281661]
- Cancer Research UK
- Cancer Research UK [15679] Funding Source: researchfish
- European Research Council (ERC) [281661] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
ATM, the protein kinase mutated in the rare human disease ataxia telangiectasia (A-T), has been the focus of intense scrutiny over the past two decades. Initially this was because of the unusual radiosensitive phenotype of cells from A-T patients, and latterly because investigating ATM signalling has yielded valuable insights into the DNA damage response, redox signalling and cancer. With the recent explosion in genomic data, ATM alterations have been revealed both in the germline as a predisposing factor for cancer and as somatic changes in tumours themselves. Here we review these findings, as well as advances in the understanding of ATM signalling mechanisms in cancer and ATM inhibition as a strategy for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available